baha the information company

baha est l'un des principaux fournisseurs de données de marché en temps réel, d'actualités financières, de technologies et de solutions pour le secteur financier. baha propose des plateformes de données en temps réel pour les professionnels, des données sur les marchés financiers du monde entier couvrant plus de 12 millions d'instruments financiers sur plus de 150 bourses, ainsi que des actualités de dernière minute 24/7 avec une couverture mondiale et des applications web et mobiles gratuites. Sur un total d'environ 200 fournisseurs de données en temps réel dans le monde, seuls Reuters 1851, Bloomberg 1981 et maintenant baha en 2021 ont porté le nom du fondateur.

Neovacs SA/ FR001400MV37 /

12/11/2024 17:35:27	Chg. 0.0000	Volume	Bid17:40:00	Demandez à17:35:49	Haut	Bas
0.0002EUR	0.00%	108.4 Mio. Chiffrre d'affaires: 21,922.8601	0.0001Bid taille: 509.21 Mio.	0.0002Ask la taille: 27.5 Mio.	0.0003	0.0002

GlobeNewswire 29/07/2019 Unum Therapeutics Announces New Appointments to its Board of Directors

TeleTrader 11/02/2019 Euronext reports technical glitch in market data

GlobeNewswire 08/01/2019 NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/I...

GlobeNewswire 11/12/2018 Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase...

GlobeNewswire 20/11/2018 Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vacci...

GlobeNewswire 15/11/2018 Human Vaccines - 2018 Global Strategic Business Report Covering 2016-2024: Increasing Need for Vacci...

GlobeNewswire 07/11/2018 Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vac...

GlobeNewswire 30/10/2018 NEOVACS : HALF-YEAR 2018 FINANCIAL RESULTS

GlobeNewswire 11/10/2018 NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT OF ITS IFNalpha KINOID IN SOUTH KOREA WITH ITS...

GlobeNewswire 11/09/2018 NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE...

GlobeNewswire 03/07/2018 NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS

GlobeNewswire 15/05/2018 NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION IN EUROPE AND JAPAN

GlobeNewswire 30/03/2018 NEOVACS PROVIDES CORPORATE UPDATE AND REPORTS FULL-YEAR 2017 FINANCIAL RESULTS

GlobeNewswire 22/02/2018 NEOVACS STRENGTHENS ITS INTELLECTUAL PROPERTY IN THE USA

GlobeNewswire 21/02/2018 Back of the Eye Disorders Markets, 2030

GlobeNewswire 16/02/2018 NEOVACS :2018 Financial Calendar

GlobeNewswire 13/02/2018 Neovacs Announces Positive Data Review from Last IDSMB Review Prior to Final Results of Phase IIb Cl...

GlobeNewswire 16/01/2018 NEOVACS : STRENGTHENED ITS INTELLECTUAL PROPERTY IN RUSSIA

GlobeNewswire 05/01/2018 miRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris

GlobeNewswire 12/12/2017 NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN TYPE 1 DIABETES

GlobeNewswire 30/10/2017 ERRATUM: NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS

GlobeNewswire 27/10/2017 NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS

GlobeNewswire 04/08/2017 NEOVACS ANNOUNCES THE CLOSING OF A €6.0 MILLION PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIO...

GlobeNewswire 31/07/2017 NEOVACS : SUCCESSFULLY RAISES €6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONA...

GlobeNewswire 19/07/2017 Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoid Clinical Development...

Neovacs SA/ FR001400MV37 /

Si vous souhaitez recevoir une réponse à vos commentaires, veuillez indiquer votre courriel.